logo
Twitter
Discord
Email
logo
STAAR Surgical Company

STAAR Surgical Company

NASDAQ•STAA
CEO: Mr. Thomas G. Frinzi
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Listing Date: 1992-02-24
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Contact Information
25651 Atlantic Ocean Drive, Lake Forest, CA, 92630, United States
626-303-7902
www.staar.com
Market Cap
$1.19B
P/E (TTM)
-12.6
76.8
Dividend Yield
--
52W High
$30.81
52W Low
$13.50
52W Range
62%
Rank39Top 29.7%
4.6
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 4.6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q4 2025 Data

Revenue

$94.73B+193428.09%
4-Quarter Trend

EPS

$179.40-26100.00%
4-Quarter Trend

FCF

$0.00-100.00%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Nine Month Sales Decline Net sales $181.6M, down 31.4% for nine months, driven by China distributor inventory normalization and payment timing.
Operating Performance Deterioration Nine months resulted in a Net Loss of ($62.1M), compared to $14.0M income prior year period.
Cash Position Strengthened Ending cash $176.2M, increased $32.0M over prior year, supported by strong investing cash flows.
Restructuring Charges Recognized Recognized $27.9M in restructuring and impairment charges during nine months related to workforce realignment efforts.

Risk Factors

Alcon Merger Uncertainty Merger completion subject to stockholder vote and regulatory approvals; facing opposition from Broadwood Group activism.
China Sales Volatility Risk Future sales depend on resolving China tariff situation and managing shift to smaller, frequent inventory purchases.
Significant Merger Transaction Costs Incurred $5.9M in professional service expenses for the Alcon merger during the quarter ended September 2025.

Outlook

China Inventory Strategy Shift Implementing consignment inventory in China to align distributor purchases closer to actual procedural volumes.
Merger Closing Conditions Focus remains on satisfying closing conditions, including stockholder adoption, for the proposed transaction with Alcon.
Cost Reduction Realignment Leadership realignment efforts substantially completed as of June 2025, aiming for sustainable profitable growth trajectory.

Peer Comparison

Revenue (TTM)

STAAR Surgical CompanySTAA
$94.91B
+30136.8%
Neogen CorporationNEOG
$886.89M
-2.8%
OPKO Health, Inc.OPK
$642.07M
-9.7%

Gross Margin (Latest Quarter)

STAAR Surgical CompanySTAA
82.2%
+17.6pp
Establishment Labs Holdings Inc.ESTA
70.1%
+6.2pp
BioLife Solutions, Inc.BLFS
64.6%
-2.3pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
ESTA$2.11B-25.9-253.8%0.9%
AZTA$1.61B-27.2-3.5%2.5%
TSHA$1.52B-20.5-67.3%5.2%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
1205.4%
Strong Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
25%
Cash Flow Needs Attention

Research & Insights

Next earnings:Feb 10, 2026
|
EPS:$0.14
|
Revenue:-
Reports
All Years
  • Form 10-Q - Q3 2025

    Period End: Sep 26, 2025|Filed: Nov 5, 2025|
    Revenue: $94.73M+6.9%
    |
    EPS: $0.18-10.0%
    Meet
  • Form 10-Q - Q3 2025

    Period End: Jun 27, 2025|Filed: Aug 6, 2025|Refer to amended data
  • Form 10-Q - Q1 2025

    Period End: Mar 28, 2025|Filed: May 7, 2025|
    Revenue: $42.59M-44.9%
    |
    EPS: $-1.10+1510.5%
    Miss
  • Form 10-K - FY 2024

    Period End: Dec 27, 2024|Filed: Feb 21, 2025|
    Revenue: $313.90M-2.6%
    |
    EPS: $-0.41-193.2%
    Miss
  • Form 10-Q - Q3 2024

    Period End: Sep 27, 2024|Filed: Oct 30, 2024|
    Revenue: $88.59M+10.3%
    |
    EPS: $0.20+101.8%
    Beat
  • Form 10-Q - Q2 2024

    Period End: Jun 28, 2024|Filed: Aug 7, 2024|
    Revenue: $99.01M+7.3%
    |
    EPS: $0.15+15.4%
    Miss
  • Form 10-Q - Q1 2024

    Period End: Mar 29, 2024|Filed: May 7, 2024|
    Revenue: $77.36M+5.2%
    |
    EPS: $-0.07-221.5%
    Miss
  • Form 10-K - FY 2023

    Period End: Dec 29, 2023|Filed: Feb 27, 2024|
    Revenue: $322.42M+13.4%
    |
    EPS: $0.44-47.0%
    Beat